Mark A. Goldsmith

Chief Executive Officer, President, and Chair at Revolution Medicines

Board

Since November 2014

Age

62 years

Education

Holds an A.B. in Biology from Princeton University and both an M.D. and a Ph.D. in Microbiology and Immunology from the University of California, San Francisco School of Medicine.

Tenure

Joined RVMD in November 2014 as Chief Executive Officer and President, and was later appointed Chair of the Board in 2020.

Also at Revolution Medicines

Jack Anders

Chief Financial Officer

Jeff Cislini

Senior Vice President, General Counsel, and Secretary

Jing Yi

Senior Vice President, Head of Program Leadership

About

Mark A. Goldsmith has an extensive academic background, beginning with an A.B. in Biology from Princeton University followed by both an M.D. and a Ph.D. in Microbiology and Immunology from the University of California, San Francisco School of Medicine. His early career was marked by leadership in medical research and clinical practice, providing a strong foundation in both scientific inquiry and patient care.

In his professional career, he joined RVMD in November 2014 as the Chief Executive Officer and President, later being appointed Chair of the Board in 2020. His leadership has been instrumental in steering the company through important milestones in the development of targeted therapies for RAS-addicted cancers.

Prior to his tenure at RVMD, he held significant roles at companies such as Constellation Pharmaceuticals, Third Rock Ventures, Global Blood Therapeutics, and Nurix, Inc., where he contributed to strategic growth and innovation in the biotechnology sector. His varied experience across executive, board, and operational roles underscores his breadth of expertise in both medicine and business, and continues to influence his contributions to the biotech industry.

$RVMD Performance Under Mark A. Goldsmith

Past Roles

Organization	Role	Date Range	Details
Constellation Pharmaceuticals, Inc.	Chairman / Interim Executive Chairman	2012–July 2021	Chairman from 2012–June 2016 and March 2017–July 2021; Interim Executive Chairman from June 2016–March 2017
Constellation Pharmaceuticals, Inc.	President and Chief Executive Officer	2009–2012	Publicly traded biopharmaceutical company prior to its acquisition by MorphoSys AG
Global Blood Therapeutics	President and Chief Executive Officer	2012–2014	Also served as a board member during the same period
Global Blood Therapeutics	Member of the Board of Directors	2012–2014
Nurix, Inc.	President and Chief Executive Officer	2012–2014
Nurix, Inc.	Member of the Board of Directors	2012–2016
Third Rock Ventures	Partner	2013–2015
Third Rock Ventures	Venture Partner	2012–2013
Gladstone Institute of Virology and Immunology	Led Medical Research Laboratory	N/A	Academic research role
University of California, San Francisco (UCSF)	Faculty of School of Medicine	N/A	Practiced medicine and worked at San Francisco General Hospital
Multiple Pharmaceutical and Biotechnology Companies (Consultant)	Consultant	N/A	Served as a consultant to various leading companies

External Roles

Organization	Role	Date Range
Nura Bio Inc.	Board of Directors	Since February 2018

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$635,000	Annually	Fixed annual salary determined during the annual compensation review
All Other Compensation	$7,000	Annually	Company matching contributions to the 401(k) plan

Performance Compensation

Data from FY 2023

Annual Cash Incentives

Parameter	Value	Additional Details
Target Annual Cash Incentive	$381,000	60% of base salary
Achievement Level	126%	Based on overall Company performance objectives
Earned Annual Cash Incentive	$477,100	Payout determined after achieving 126% of the performance goals
Performance Metrics	Company performance objectives	No additional weight or threshold details provided
Evaluation Period	Annually	Assessed at the end of the fiscal year
Vesting Schedule	N/A	Cash incentive payments are not subject to vesting [N/A]

Long-Term Equity Incentives

Parameter	Stock Options	RSUs
Number of Shares	363,000	104,000
Vesting Schedule	Monthly vesting over 48 months starting March 1, 2023	Quarterly vesting over 16 quarters starting March 15, 2023
Grant Date Fair Value	$6,540,026	$2,756,000
Grant Date Stock Price	$26.50	N/A
Performance Conditions	None – vesting based on continued service	None – vesting based on continued service

The Annual Cash Incentives are performance-based with targets derived from Company performance objectives, while the Long-Term Equity Incentives are granted on a service basis without performance thresholds.